Working... Menu

Impact of MELD Score for 700 Consecutive Liver Transplantations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02548130
Recruitment Status : Completed
First Posted : September 14, 2015
Last Update Posted : September 14, 2015
Information provided by (Responsible Party):
Luc Massicotte, Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary:
The goal of this observational study was to evaluate the impact of the adoption of the MELD system to prioritize patients on the waiting list for OLT on survival for 700 consecutive liver transplantations. Survival was evaluated on the waiting list, one month, and one year after the transplantation. Another goal was to look at blood losses and transfusion requirement after the adoption of the MELD score. The hypothesis was the MELD system will ameliorate the survival rate on the waiting, but the post-OLT will be worse. Blood losses and transfusions could be worse with the MELD system.

Condition or disease Intervention/treatment
End Stage Liver Disease Other: MELD score

  Show Detailed Description

Layout table for study information
Study Type : Observational
Actual Enrollment : 700 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Impact of the Introduction of the MELD Score to Prioritize the Waiting List on Survival, Blood Losses, And Transfusion Requirement for 700 Consecutive Liver Transplantations, Observational Study
Study Start Date : October 2002
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Patients before MELD score
Recipients before the MELD score
Patients after the MELD score
Recipients after the MELD score
Other: MELD score
introduction of MELD score

Primary Outcome Measures :
  1. Survival; [ Time Frame: one year ]

Secondary Outcome Measures :
  1. Bleeding [ Time Frame: Per-operatively ]
  2. transfusion of blood products [ Time Frame: Per0operatively ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   17 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients for a liver transplantation

Inclusion Criteria:

  • Patients for a liver transplantation at the investigators' institution

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02548130

Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Layout table for investigator information
Principal Investigator: Manon Choiniere, PhD CrCHUM

Layout table for additonal information
Responsible Party: Luc Massicotte, Anesthesiologist, Centre hospitalier de l'Université de Montréal (CHUM) Identifier: NCT02548130     History of Changes
Other Study ID Numbers: Centre CHUM
First Posted: September 14, 2015    Key Record Dates
Last Update Posted: September 14, 2015
Last Verified: September 2015

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
End Stage Liver Disease
Digestive System Diseases
Liver Failure
Hepatic Insufficiency